• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

c-met作为食管癌患者预后指标的系统评价：一项荟萃分析研究

Systematic review of c-met as a prognostic indicator in esophageal cancer patients: a meta-analysis study.

作者信息

Yu Zipu, Zhang Guofei, Shen Gang

机构信息

Department of Thoracic Surgery2nd Affiliated Hospital, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang, China.

出版信息

Discov Oncol. 2025 Sep 26;16(1):1716. doi: 10.1007/s12672-025-03398-y.

DOI:10.1007/s12672-025-03398-y
PMID:41003868
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12474832/
Abstract

OBJECTIVES

To evaluate c-met expression as a reliable prognostic indicator for survival in esophageal cancer patients.

METHODS

Eligible articles from relevant studies or databases were retrieved via systematical search. The association between c-met expression and survival results was evaluated by pooled effect in esophageal cancer patients. A fixed-effects or random-effects model was used to calculate the pooled risk ratios (RRs) and corresponding 95% confidence intervals (CIs).

RESULTS

13 studies were up to the selection criteria. Our meta-analysis indicated that c-met positive expression correlated with lower overall survival (RR = 0.40; 95%CI: 0.25-0.63), disease-free-survival (RR = 0.30; 95%CI: 0.21-0.44), disease specific survival (RR = 0.53; 95%CI: 0.35-0.80) in esophageal cancer patients.

CONCLUSION

C-met positive expression indicates a poor prognosis in esophageal cancer patients. Further studies are required to confirm our result.

摘要

目的

评估c-met表达作为食管癌患者生存的可靠预后指标。

方法

通过系统检索从相关研究或数据库中获取符合条件的文章。通过汇总效应评估食管癌患者中c-met表达与生存结果之间的关联。采用固定效应或随机效应模型计算汇总风险比（RRs）及相应的95%置信区间（CIs）。

结果

13项研究符合入选标准。我们的荟萃分析表明，c-met阳性表达与食管癌患者较低的总生存期（RR = 0.40；95%CI：0.25 - 0.63）、无病生存期（RR = 0.30；95%CI：0.21 - 0.44）、疾病特异性生存期（RR = 0.53；95%CI：0.35 - 0.80）相关。

结论

c-met阳性表达表明食管癌患者预后不良。需要进一步研究来证实我们的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/bfad1f65dedc/12672_2025_3398_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/722b2dbc2d62/12672_2025_3398_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/7448ca10f41d/12672_2025_3398_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/cb13f21efb24/12672_2025_3398_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/85d57a35fa31/12672_2025_3398_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/75c61cfdea57/12672_2025_3398_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/bfad1f65dedc/12672_2025_3398_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/722b2dbc2d62/12672_2025_3398_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/7448ca10f41d/12672_2025_3398_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/cb13f21efb24/12672_2025_3398_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/85d57a35fa31/12672_2025_3398_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/75c61cfdea57/12672_2025_3398_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d8c/12474832/bfad1f65dedc/12672_2025_3398_Fig6_HTML.jpg

相似文献

1
Systematic review of c-met as a prognostic indicator in esophageal cancer patients: a meta-analysis study.c-met作为食管癌患者预后指标的系统评价：一项荟萃分析研究
Discov Oncol. 2025 Sep 26;16(1):1716. doi: 10.1007/s12672-025-03398-y.
2
Screening for prostate cancer.前列腺癌筛查
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3.
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.阿司匹林用于心血管疾病和癌症一级预防的预防性使用：系统评价和综述概述。
Health Technol Assess. 2013 Sep;17(43):1-253. doi: 10.3310/hta17430.
5
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
6
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.用于预防成人和儿童艰难梭菌相关性腹泻的益生菌
Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. doi: 10.1002/14651858.CD006095.pub4.
7
Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation.性别作为肾移植后同种异体移植及患者相关预后的预测因素。
Cochrane Database Syst Rev. 2024 Dec 19;12(12):CD014966. doi: 10.1002/14651858.CD014966.pub2.
8
Electronic cigarettes for smoking cessation.电子烟戒烟。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD010216. doi: 10.1002/14651858.CD010216.pub7.
9
Electronic cigarettes for smoking cessation.用于戒烟的电子烟。
Cochrane Database Syst Rev. 2025 Jan 29;1(1):CD010216. doi: 10.1002/14651858.CD010216.pub9.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.

本文引用的文献

1
Tumor-associated lymphatic vessel density is a postoperative prognostic biomarker of hepatobiliary cancers: a systematic review and meta-analysis.肿瘤相关淋巴管密度是肝胆癌术后的预后生物标志物：一项系统评价和荟萃分析。
Front Immunol. 2025 Jan 7;15:1519999. doi: 10.3389/fimmu.2024.1519999. eCollection 2024.
2
Tumor-associated lymphatic vessel density is a reliable biomarker for prognosis of esophageal cancer after radical resection: a systemic review and meta-analysis.肿瘤相关淋巴管密度是食管癌根治术后预后的可靠生物标志物：系统评价和荟萃分析。
Front Immunol. 2024 Sep 20;15:1453482. doi: 10.3389/fimmu.2024.1453482. eCollection 2024.
3
A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
c-Met抑制剂替凡替尼联合FOLFOX治疗既往未治疗的远端食管、胃食管交界或胃转移性腺癌患者的II期研究
Cancer Invest. 2017 Aug 9;35(7):463-472. doi: 10.1080/07357907.2017.1337782. Epub 2017 Jun 29.
4
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.MET酪氨酸激酶受体表达及扩增作为胃食管腺癌生存的预后生物标志物
Cancer. 2017 May 15;123(6):1061-1070. doi: 10.1002/cncr.30437. Epub 2016 Dec 7.
5
C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome.C-Met作为食管鳞状细胞癌的分子标志物及其与临床结局的关联。
J Cancer. 2016 Mar 18;7(5):587-94. doi: 10.7150/jca.13687. eCollection 2016.
6
Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma.表皮生长因子受体（EGFR）和c-Met在食管鳞状细胞癌进展中的预后影响及潜在相互作用
Tumour Biol. 2016 Jul;37(7):9771-9. doi: 10.1007/s13277-015-4692-4. Epub 2016 Jan 25.
7
Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer.MET靶向对肿瘤相关血管生成及MET突变驱动的肝癌模型生长的影响
Genes Cancer. 2015 Jul;6(7-8):317-327. doi: 10.18632/genesandcancer.74.
8
Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance.非小细胞肺癌中 MET 通路失调：对药物靶向和耐药性的影响。
Transl Lung Cancer Res. 2015 Jun;4(3):242-52. doi: 10.3978/j.issn.2218-6751.2015.03.05.
9
c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target.c-Met在食管鳞状细胞癌中的作用：一个独立的预后因素和潜在的治疗靶点。
BMC Cancer. 2015 Jun 3;15:451. doi: 10.1186/s12885-015-1450-3.
10
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.携带导致第14外显子跳跃的MET突变的IV期肺腺癌患者对MET抑制剂的反应。
Cancer Discov. 2015 Aug;5(8):842-9. doi: 10.1158/2159-8290.CD-14-1467. Epub 2015 May 13.